ClinicalTrials.gg
RecruitingNCT07037017Updated Jun 25, 2025

CBT Effects on Neural, Physiological, and Attentional Responses in Anorexia Nervosa

An interventional study of Cognitive-Behavioral Therapy in Eating Disorders (Excluding Anorexia Nervosa), sponsored by Istanbul Nisantasi University. Recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2025-06-25.

Sponsored by Istanbul Nisantasi University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 2 months ago, but the record still lists the study as recruiting.
  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Feeding and Eating Disorders with a site in Turkey — 2 open to participants now, 4 under way, none of them phase 3. Feeding and Eating Disorders · Turkey.

Started
2025
with 4 others
No phase
9 of 20
2 open now
Registered
14th of 20
by date
Lead sponsor
1 of 20
Istanbul Nisantasi University

Among the 20 studies in Feeding and Eating Disorders with a site in Turkey, this one is one of 5 that started in 2025, is one of 9 with no phase, and was the 14th registered.

Feeding and Eating Disorders

645 studies on the registry are indexed under Feeding and Eating Disorders; 151 are open to participants now.

Browse Feeding and Eating Disorders studies →

Open to participants now

2 of the 20 studies in Feeding and Eating Disorders with a site in Turkey are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 99 Feeding and Eating Disorders studies recruiting now, 31 (31%) set no upper age limit and 66 (67%) stop at 75 or younger; 45 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 35 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Feeding and Eating Disorders with a site in Turkey, or all of them as a file.
02

Study summary

This randomized controlled trial investigates the neurophysiological, physiological, and attentional effects of Cognitive-Behavioral Therapy (CBT) in individuals with restrictive-type anorexia nervosa (AN). The study compares two groups: one receiving a 12-week CBT intervention, and one placed on a waitlist (no active treatment during the study period). All participants undergo pre- and post-intervention assessments using electroencephalography (EEG), galvanic skin response (GSR), and eye-tracking while exposed to visual stimuli related to food, body image, and self-appearance. The primary outcomes include neural changes in attention and emotional processing (P300, LPP, frontal alpha asymmetry), physiological arousal (skin conductance), and visual attention biases (fixation duration and gaze distribution). The aim is to determine whether CBT leads to measurable improvements in neurobiological and attentional mechanisms related to body image disturbance and food-related anxiety in AN, contributing to biomarker-informed psychotherapy approaches.

Read the detailed description

Anorexia nervosa (AN) is a severe psychiatric disorder characterized by distorted body image, food restriction, and intense fear of weight gain. Despite the effectiveness of Cognitive-Behavioral Therapy (CBT) in targeting maladaptive cognitions and behaviors, its underlying neurophysiological mechanisms remain insufficiently understood. This study aims to evaluate the effects of a 12-week CBT intervention on neural, physiological, and attentional responses in individuals with restrictive-type AN using a randomized controlled trial design.

Sixty female participants (aged 18-35) with restrictive-type AN will be recruited and randomly assigned to one of two groups: a CBT intervention group (n = 30) and a waitlist control group (n = 30). Both groups will undergo baseline and post-intervention assessments using EEG, GSR, and eye-tracking. The CBT intervention will consist of weekly 60-minute sessions for 12 weeks, delivered by trained therapists, and will target body image distortion, cognitive restructuring, exposure to food-related stimuli, emotional regulation, and avoidance behaviors.

During the experimental task, participants will view a series of visual stimuli including (1) self-images (unaltered, altered-thin, altered-overweight), (2) food images (low- vs. high-calorie), and (3) images of other female bodies (thin vs. normal weight). EEG markers of interest include P300 (attentional salience), Late Positive Potential (LPP; sustained emotional reactivity), and frontal alpha asymmetry (indicative of affect regulation and self-referential processing). It is hypothesized that CBT will lead to reductions in P300 and LPP amplitudes and an increase in left-frontal cortical activity, indicating enhanced emotional control and reduced fixation on thin-ideal stimuli.

GSR will be used to assess physiological arousal in response to distressing stimuli. It is expected that post-CBT participants will exhibit lower skin conductance responses (SCRs) to body and food images, indicating improved autonomic regulation. Eye-tracking data will capture fixation durations and gaze patterns. Participants in the CBT group are expected to show less visual attention toward "problematic" body areas (waist, stomach, thighs) and reduced avoidance of high-calorie food images compared to the waitlist group.

Participants will also complete standardized psychometric instruments including the Eating Disorder Examination Questionnaire (EDE-Q), Beck Depression Inventory-II (BDI-II), Beck Anxiety Inventory (BAI), the Yale-Brown Obsessive-Compulsive Scale for Body Dysmorphic Disorder (YBOCS-BDD), and the Cognitive Emotion Regulation Questionnaire (CERQ) at both time points.

This trial will provide critical insights into the neurophysiological and attentional mechanisms of CBT in AN, aiming to identify objective biomarkers of therapeutic change. Results may inform precision-based treatment models and support the development of digitally enhanced or neuromodulation-augmented therapies for eating disorders.

03

Conditions studied

  • Eating Disorders (Excluding Anorexia Nervosa)

Keywords

  • Cognitive Behavioral Therapy (CBT)
  • EEG
  • Eye-Tracking
  • Galvanic Skin Response (GSR)
  • Body Image
04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female participants aged 18 to 35
  • Meeting diagnostic criteria for restrictive-type anorexia nervosa
  • (BMI) between 15.0 and 18.5
  • Medically stable to participate in psychological and neurophysiological assessments
  • Willingness to participate in weekly therapy sessions (for the CBT group) and to complete pre- and post-assessments
  • Ability to provide

Exclusion criteria

Exclusion Criteria:

  • Current or past diagnosis of bulimia nervosa, binge-eating disorder, or other eating disorders
  • Presence of comorbid severe psychiatric disorders (e.g., psychosis, bipolar disorder, substance use disorder)
  • History of neurological illness or traumatic brain injury
  • Use of psychotropic medication within the last 6 weeks
  • Prior participation in structured Cognitive-Behavioral Therapy for an eating disorder
  • Pregnancy
  • Visual or neurological impairments that would prevent accurate EEG, GSR, or eye-tracking recordings
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    CBT Intervention Group

    Participants diagnosed with restrictive-type anorexia nervosa will receive 12 weekly individual Cognitive-Behavioral Therapy (CBT) sessions. Each session will last approximately 60 minutes and be delivered by a trained therapist. The CBT protocol targets body image distortion, cognitive restructuring of maladaptive beliefs, exposure to food-related stimuli, emotional regulation strategies, and behavioral experiments to reduce avoidance. Pre- and post-treatment neurophysiological (EEG), physiological (GSR), and attentional (eye-tracking) assessments will be conducted.

    Behavioral: Cognitive-Behavioral Therapy

  • No intervention
    Waitlist Control Group

    Participants diagnosed with restrictive-type anorexia nervosa will be placed on a waitlist and will not receive any structured psychological intervention during the 12-week study period. They will complete the same neurophysiological (EEG), physiological (GSR), and attentional (eye-tracking) assessments at baseline and at the 12-week follow-up.

Interventions

  • BehavioralCognitive-Behavioral Therapy

    Manualized 12-week CBT protocol focused on reducing body image disturbance, distorted beliefs about food and appearance, and avoidance behaviors in individuals with anorexia nervosa. The intervention incorporates psychoeducation, cognitive restructuring, emotional regulation, food exposure, and body image work.

06

What researchers measure

Primary outcomes

  1. Change in EEG P300 amplitude in response to body image stimuli

    P300 amplitudes will be extracted from EEG data during visual exposure to body image stimuli. Reduced amplitudes post-CBT are hypothesized to indicate reduced attentional salience and hyperfocus on appearance-related cues. P300 amplitudes will be extracted from EEG data during visual exposure to body image stimuli. Reduced amplitudes post-CBT are hypothesized to indicate reduced attentional salience and hyperfocus on appearance-related cues.

    Time frame: aseline and Week 12

  2. Change in Late Positive Potential (LPP) amplitude to body and food stimuli

    LPP amplitudes will be measured during viewing of thin, overweight, and food-related images. A reduction post-CBT suggests decreased sustained emotional reactivity to distressing visual input.

    Time frame: Baseline and Week 12

  3. Change in frontal alpha asymmetry during self-image viewing

    Frontal alpha asymmetry (FAA), computed from EEG data, will be used to index emotional regulation. An increase in left-dominant FAA is expected post-CBT, reflecting enhanced emotional control and positive self-perception.

    Time frame: Baseline and Week 12

  4. Change in skin conductance response (SCR) to body and food stimuli

    Skin conductance responses will be measured via GSR during visual exposure to self-body, other-body, and food stimuli. Decreased SCR amplitudes post-CBT will indicate reduced physiological arousal and distress.

    Time frame: Baseline and Week 12

  5. Change in fixation duration on weight-related body areas

    Eye-tracking will assess gaze fixation duration on areas of interest (waist, thighs, stomach). Post-CBT reductions in fixation on these regions suggest reduced attentional bias toward body dissatisfaction zones.

    Time frame: Baseline and Week 12 Baseline and Week 12

Secondary outcomes

  1. Change in Eating Disorder Examination Questionnaire (EDE-Q) scores

    The EDE-Q assesses eating disorder symptoms across four subscales: Restraint, Eating Concern, Weight Concern, and Shape Concern. Each item is rated from 0 (no pathology) to 6 (high pathology). Global score ranges from 0 to 6. Higher scores indicate greater eating pathology. A reduction in post-treatment scores indicates improvement in eating disorder symptoms.

    Time frame: Baseline and Week 12

  2. Change in Beck Depression Inventory-II (BDI-II) scores

    The BDI-II consists of 21 items scored from 0 to 3, yielding a total score between 0 and 63. Higher scores reflect more severe depressive symptoms: 0-13: minimal 14-19: mild 20-28: moderate 29-63: severe A decrease in BDI-II score post-CBT is expected, reflecting reduced depressive symptoms.

    Time frame: Baseline and Week 12

  3. Change in Beck Anxiety Inventory (BAI) scores

    The BAI includes 21 items rated from 0 to 3, with a total score ranging from 0 to 63. Higher scores indicate more severe anxiety: 0-7: minimal 8-15: mild 16-25: moderate 26-63: severe Post-CBT reductions in BAI scores suggest improved anxiety regulation.

    Time frame: Baseline and Week 12

  4. Change in Yale-Brown Obsessive Compulsive Scale - Body Dysmorphic Disorder Version (YBOCS-BDD) scores

    The YBOCS-BDD contains 12 items rated from 0 to 4, yielding a total score range of 0 to 48. Higher scores reflect greater severity of body image-related obsessions and compulsions. Scores ≥ 20 are considered moderate to severe. Post-treatment reductions reflect decreased symptom severity.

    Time frame: Baseline and Week 12

  5. Change in Cognitive Emotion Regulation Questionnaire (CERQ) scores

    The CERQ includes 36 items rated from 1 (almost never) to 5 (almost always), across 9 subscales (e.g., catastrophizing, reappraisal, rumination). Subscale scores range from 4 to 20. Higher scores in adaptive subscales and lower scores in maladaptive subscales post-CBT indicate improved emotional coping. The CERQ includes 36 items rated from 1 (almost never) to 5 (almost always), across 9 subscales (e.g., catastrophizing, reappraisal, rumination). Subscale scores range from 4 to 20. Higher scores in adaptive subscales and lower scores in maladaptive subscales post-CBT indicate improved emotional coping.

    Time frame: Baseline and Week 12

  6. Change in subjective distress ratings on Visual Analog Scale (VAS)

    The VAS is a self-reported 0-10 scale used to assess momentary emotional distress following exposure to visual stimuli. 0 = no distress 10 = extreme distress Lower VAS scores after CBT indicate increased emotional tolerance of body and food-related images.

    Time frame: Immediately after the experimental task at both baseline and Week 12

07

Study locations

1 of 1 sites recruiting
  • Üsküdar University Neuro Marketing Lab.
    Istanbul, Turkey (Türkiye)
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) for all primary and secondary outcome measures (EEG, GSR, eye-tracking, and psychometric scores) will be shared upon reasonable request. Data will be shared in compliance with institutional ethics and data protection regulations.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code

Time frame: IPD and supporting materials will be available beginning 6 months after publication of the primary results and will remain available for up to 5 years upon request.

Access criteria: Qualified researchers affiliated with academic institutions may request access to the IPD and supporting materials for ethically approved secondary analyses. Requests must include a brief research proposal and will be reviewed by the study investigators. Data will be shared via secure institutional transfer platforms upon data use agreement. Qualified researchers affiliated with academic institutions may request access to the IPD and supporting materials for ethically approved secondary analyses. Requests must include a brief research proposal and will be reviewed by the study investigators. Data will be shared via secure institutional transfer platforms upon data use agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Sep 2025, 4 months after the start.

Of 267 non-industry interventional studies with no phase under Feeding and Eating Disorders, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's planned 4 months is below that.

Counting every sponsor, half of 272 studies reached it within 28 months; a quarter within 14 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2025
First posted
Jun 25, 2025
StartActual
May 15, 2025
Primary completionEst.
Sep 15, 2025
CompletionEst.
Oct 15, 2025
Last update
Jun 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07037017
Lead sponsor
Istanbul Nisantasi University
Collaborators
Uskudar University, Beykoz University
Responsible party
Metin Çınaroğlu (Assistant Professor, Istanbul Nisantasi University) — Principal investigator
First posted
Jun 25, 2025
Start date
May 15, 2025
Primary completion
Sep 15, 2025 (estimated)
Completion
Oct 15, 2025 (estimated)
Last update
Jun 25, 2025

Study contacts

Metin Çınaroğlu, Phd
Contact
metincinaroglu@gmail.com
00905324732070
Selami Varol Ülker, Phd
Contact
selamivarol.ulker@uskudar.edu.tr
00905364360941
Gökben Hızlı Sayar, Professor
study chair · Üsküdar University
Eda Yılmazer, Phd
study director · Beykoz University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion